Entry Detail



General Information

Database ID:exR0359434
RNA Name:ADNP
RNA Type:mRNA
Chromosome:chr20
Starnd:-
Coordinate:
Start Site(bp):50888916End Site(bp):50931437
External Links:ENSG00000101126



Disease Information

Disease Name:Amyotrophic Lateral Sclerosis
Disease Category:Nervous System Diseases
MeSH ID:D000690
Type:Diseases Category/Nervous System Diseases
Alias:Sclerosis, Amyotrophic Lateral//Gehrig's Disease//Gehrig Disease//Gehrigs Disease//Charcot Disease//Motor Neuron Disease, Amyotrophic Lateral Sclerosis//Lou Gehrig's Disease//Lou-Gehrigs Disease//Disease, Lou-Gehrigs//ALS - Amyotrophic Lateral Sclerosis//ALS Amyotrophic Lateral Sclerosis//Lou Gehrig Disease//Amyotrophic Lateral Sclerosis, Guam Form//Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 1//Amyotrophic Lateral Sclerosis Parkinsonism Dementia Complex 1//Guam Form of Amyotrophic Lateral Sclerosis//Guam Disease//Disease, Guam//Amyotrophic Lateral Sclerosis, Parkinsonism-Dementia Complex of Guam//Amyotrophic Lateral Sclerosis, Parkinsonism Dementia Complex of Guam//Amyotrophic Lateral Sclerosis With Dementia//Dementia With Amyotrophic Lateral Sclerosis



Expression Detail

GEO ID:GSE121519
Description:Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid.
Experimental Design:Disease vs Control
Case Disease Type:Amyotrophic Lateral Sclerosis
Case Disease SubType:NA
Case Sample:Amyotrophic Lateral Sclerosis
Control Sample:Healthy
Number of Case:4
Number of Control:4
Number of Samples:8





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
HNRNPA3
chr2
177212563
177223958
+
GRPEL1
chr4
7058895
7068064
-
SNRPA
chr19
40750637
40765389
+
IL9R
chrX
155997581
156010817
+
RPLP0
chr12
120196699
120201235
-
COG8
chr16
69320140
69339667
-
CREBRF
chr5
173056352
173139284
+
RREB1
chr6
7107597
7251980
+
LMO2
chr11
33858576
33892076
-
HDGF
chr1
156742109
156766925
-
TUBA1B
chr12
49127782
49131397
-
ZFAND3
chr6
37819727
38154624
+
CUL9
chr6
43182184
43224587
+
SLC39A10
chr2
195575977
195737702
+
GATD1
chr11
767220
777488
-
POLR2B
chr4
56977722
57031158
+
HPS5
chr11
18278668
18322198
-
KDM3B
chr5
138352685
138437028
+
CCT3
chr1
156308968
156367873
-
ACOT9
chrX
23701055
23766475
-
MTCH1
chr6
36968141
36986298
-
LRP11
chr6
149818757
149864359
-
LMAN1
chr18
59327823
59359265
-
EIF4E2
chr2
232550674
232583644
+
CBL
chr11
119206298
119313926
+
ATP5MC3
chr2
175176258
175184607
-
C18orf25
chr18
46173553
46266992
+
MAP7D1
chr1
36155579
36180849
+
HMGA1
chr6
34236873
34246231
+
PRMT3
chr11
20387558
20509338
+
miRNA targets:
miRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa-miR-17-5p
chr13
91350618
91350640
+
circRNA targets:NA
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC023509.1
chr12
53441741
53467528
+
AJ271736.1
chrX
156004218
156022236
+
AC079949.1
chr12
127142029
127146532
-
MALAT1
chr11
65497688
65506516
+
MIR17HG
chr13
91347820
91354579
+
TUG1
chr22
30969245
30979395
+
Display:



Experiment Detail

GEO ID:GSE121519
Sample Source:Cerebrospinal Fluid
Source Fraction:Exosome
Platform:GPL18573
Method:NGS
Num of detected RNA Type:2
Num of detected RNAs of this Type:17787
Sample treatment protocol:Up to 1 mL of human CSF was centrifuged at 2,000×g for 5 min and 10, 000×g for 20 min for supernatant.
RNA Extract protocol:Supernatant from final centrifugation was applied to exoRNeasy spin column and RNA was extracted.
RNA library preparation protocol:Whole cDNA amplification was performed with SMART-seq v4 Ultra Low Input RNA Kit. Illumina library was constructed with Nextera XT DNA Library Prep Kit.



Reference

PMID:30630471
Title:Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid
Author:Otake K, Kamiguchi H, Hirozane Y
Journal:BMC Med Genomics. 2019 Jan 10;12(1):7.
Description:The main purpose of this study is to established the methodology of comprehensive analysis of exosomal mRNAs in CSF by a highly sensitive next-generation sequencing.